An international team of researchers has identified three genetic variants significantly associated with higher odds of developing neuromyelitis optica spectrum disorder (NMOSD) with self-reactive antibodies against the AQP4 protein. The data also suggest that, in terms of genetic risk factors, AQP4-positive NMOSD is more similar to systemic autoimmune diseases…
Use of the approved therapy Uplizna (inebilizumab) reduces the risk of relapse and worsening disability in people with neuromyelitis optica spectrum disorder (NMOSD), regardless of whether patients had previously received conventional immunosuppressive treatments. These are the findings of a post-hoc analysis of data from the Phase 2/3…
People with neuromyelitis optica spectrum disorder (NMOSD) often experience severe fatigue, pain, anxiety, and depression that are not fully captured by standard physical disability tools used in the clinic, a study found. According to the researchers, “disability scores were weakly associated with symptom burden” on the Expanded Disability Status…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
